Salpingectomy
Salpingectomy has been studied in 13 papers since 2022: 2 observational studies in people, 9 reviews; 8 in the past year. The newest paper, Nov 9, 2026: “Risk‐reducing gynecologic surgery in hereditary cancer: Evidence, timing, and counseling”.
1 new paper in 30 daysSee all 13 papers on salpingectomy
At a glance
Reviews describe lower epithelial ovarian cancer risk with salpingectomy and prevention of high-grade serous carcinoma in average-risk women. One group reports an association with menopausal age in postmenopausal women. Modeling projects gains in quality-adjusted life-years at general-population risk but no clear cost-effectiveness benefit in that setting.
12 findings in 8 papers from 2022 to 2026, 3 of them since June 2026
The findings reach people, from one lab or study. 3 independent labs in 2 countries.
“In all the models, education, history of salpingectomy, diabetes, cardiac ischemic, and depression were significantly associated with menopausal age.”
None of its findings points the other way.
- 3 independent labs in 2 countries
- Funders: Break Through Cancer and 8 more
- 2 of 4 findings with company ties
- Humans2
- In silico1
What did studies of salpingectomy find?
6Studies of salpingectomy measured 6 outcomes, among them Cost-effectiveness, quality-adjusted life-years and ovarian cancer.
Cost-effectiveness
upin silico1no changein silico1
1 study
Cost-effectiveness
upin silico1no changein silico1
Salpingectomy improves cost-effectiveness in silico (relative risk 1.5) (ICERs $142,516-$172,112/QALY).
“At a moderately increased risk (relative risk 1.5), ICERs fell to $142,516-$172,112/QALY, making salpingectomy cost-effective at ages 45 and 50.”
In silicorelative risk 1.5
Standalone Salpingectomy for Primary Ovarian Cancer Prevention: A Cost-Effectiveness Analysis
American journal of obstetrics and gynecology
Salpingectomy showed no clear effect on cost-effectiveness in silico (general population risk) (ICERs $239,736-$288,870/QALY).
“For general population risk, standalone salpingectomy was not cost-effective in any age cohort”
In silicogeneral population risk
Standalone Salpingectomy for Primary Ovarian Cancer Prevention: A Cost-Effectiveness Analysis
American journal of obstetrics and gynecology
Quality-adjusted life-years
upin silico1
1 study
Quality-adjusted life-years
upin silico1
Salpingectomy increases quality-adjusted life-years in silico (general population risk) (0.02-0.03 QALYs).
“Incremental costs were approximately $6100-$6225 per person with gains of 0.02-0.03 QALYs.”
In silicogeneral population risk
Standalone Salpingectomy for Primary Ovarian Cancer Prevention: A Cost-Effectiveness Analysis
American journal of obstetrics and gynecology
Ovarian cancer
downin humans1
1 study
Ovarian cancer
downin humans1
Salpingectomy prevents ovarian cancer in humans during indicated benign surgery.
“Opportunistic salpingectomy during indicated benign surgery is supported as an ovarian cancer prevention strategy that preserves ovarian hormonal function”
Reviewduring indicated benign surgery
Complex benign gynecology in perimenopause: current evidence and future directions
Current opinion in obstetrics & gynecology
High-grade serous carcinoma
downin humans1
1 study
High-grade serous carcinoma
downin humans1
Salpingectomy prevents high-grade serous carcinoma in average-risk women.
“Opportunistic salpingectomy prevents HGSC in average-risk women”
Reviewin average-risk women
Academia oncology
Ovary
no changein humans1
1 study
Ovary
no changein humans1
Salpingectomy showed no clear effect on ovary in humans.
“Bilateral salpingectomy has been demonstrated to be safe with minimal added operative time, no adverse effects on ovarian function”
Reviewbilateral salpingectomyovaryfemales
FIGO position statement on opportunistic salpingectomy as an ovarian cancer prevention strategy
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Age at menopause onset
no changein humans1
1 study
Age at menopause onset
no changein humans1
Salpingectomy showed no clear effect on age at menopause onset in humans.
“Studies have demonstrated that salpingectomy was safe, cost-effective, and was not associated with an earlier age of menopause onset.”
Reviewfemales
Salpingectomy for the Primary Prevention of Ovarian Cancer: A Systematic Review
JAMA surgery
What is salpingectomy linked with?
4Studies link salpingectomy with 4 measures, among them epithelial ovarian cancer, epithelial ovarian cancer incidence and ovarian cancer.
Epithelial ovarian cancer
downin humans2
2 studies
Epithelial ovarian cancer
downin humans2
Salpingectomy lowers the risk of epithelial ovarian cancer in humans.
“supporting the benefit of complete, bilateral salpingectomy at the time of obstetric and gynecologic surgery”
Review
ACOG Clinical Practice Update: Salpingectomy for the Prevention of Epithelial Ovarian Cancer
Obstetrics and gynecology
Salpingectomy lowers the risk of epithelial ovarian cancer in average-risk women.
“Studies show that bilateral salpingectomy (BS) significantly reduces ovarian cancer incidence even in average-risk women.”
Reviewin average-risk womenbilateral salpingectomyfemales
FIGO position statement on opportunistic salpingectomy as an ovarian cancer prevention strategy
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Epithelial ovarian cancer incidence
downin humans1RR 0.223
1 study
Epithelial ovarian cancer incidence
downin humans1RR 0.223
Salpingectomy is associated with epithelial ovarian cancer incidence in humans (compared with controls without salpingectomy) (77.7% reduction; RR 0.223, 95% CI 0.182–0.274).
“Salpingectomy was associated with a 77.7% reduction in EOC incidence compared to control patients”
Reviewcompared with controls without salpingectomyfemales
Journal of the Turkish German Gynecological Association
Ovarian cancer
downin humans1−80% lower ovarian cancer risk
1 study
Ovarian cancer
downin humans1−80% lower ovarian cancer risk
Salpingectomy is associated with ovarian cancer in humans (Approximately 80% lower ovarian cancer risk).
“Salpingectomy has been associated with ovarian cancer risk reduction of approximately 80%.”
Reviewfemales
Salpingectomy for the Primary Prevention of Ovarian Cancer: A Systematic Review
JAMA surgery
Menopausal age
mixedin humans1
1 study
Menopausal age
mixedin humans1
Salpingectomy is associated with menopausal age in humans (postmenopausal women).
“In all the models, education, history of salpingectomy, diabetes, cardiac ischemic, and depression were significantly associated with menopausal age.”
Humanspostmenopausal womenfemalesn = 1,251
International journal of reproductive biomedicine
Funding
6 grants since 2019Agency for Healthcare Research and Quality$3.6MGouvernement du Canada | Canadian Institutes of Health ResearchCA$584KMedical Research Future FundA$2M
Salpingectomy for Ovarian Cancer Risk Reduction: Improving Utilization and Informed Decision-Making
Agency for Healthcare Research and QualityColumbia University Health Sciences$355K2022–2027
VetenskapsrådetUmeå UniversitetSEK 1.2M2025
Salpingectomy with delayed oophorectomy to prevent ovarian cancer (TUBA WISP II)
Medical Research Future FundUniversity of MelbourneA$2M2024–2029
Gouvernement du Canada | Canadian Institutes of Health Research2023–2026
Gouvernement du Canada | Canadian Institutes of Health ResearchUniversity of British ColumbiaCA$110K2022–2025
Outcomes following salpingectomy in BRCA1 and BRCA2 mutation carriers
Gouvernement du Canada | Canadian Institutes of Health ResearchWomen's College HospitalCA$474K2019–2024
How this record changed
Summary rewritten as its findings changed.
As it read before
A modeling study reports increased quality-adjusted life-years with salpingectomy at general-population risk, but no cost-effectiveness benefit there; cost-effectiveness improves at relative risk 1.5. A review describes lower epithelial ovarian cancer risk in humans. The Agency for Healthcare Research and Quality is named as a grant funder.
Summary written from the findings.